Monoclonal antibody

A monoclonal antibody is an antibody produced in a laboratory by a single clone of cells, designed to bind to a specific target — typically a protein on the surface of a pathogen or a cancer cell. Unlike polyclonal antibodies, which are produced by the immune system and recognize multiple epitopes on a target, monoclonal antibodies are highly specific, binding to a single epitope with high affinity. This specificity makes them powerful tools in medicine, diagnostics, and research.

The production of monoclonal antibodies involves the fusion of a B cell — which produces the desired antibody — with a myeloma cell, creating a hybridoma that can be cultured indefinitely and produce the antibody in large quantities. This technique, developed by Köhler and Milstein in 1975, earned them the Nobel Prize in Physiology or Medicine in 1984.

The systems-theoretic significance of monoclonal antibodies lies in their connection to networked regulation: the immune system itself is a networked regulatory system, in which no single lymphocyte recognizes all pathogens, but the network of diverse receptors collectively covers the antigenic space. Monoclonal antibodies are a technological intervention in this network — a way to amplify a specific regulatory response by introducing a highly specific agent into the system. They are used in cancer immunotherapy, autoimmune disease treatment, and infectious disease prevention, and they represent a paradigm of precision medicine in which the intervention is designed to match the specific molecular target.